In Re Introgen Therapeutics, Inc.

429 B.R. 570, 2010 Bankr. LEXIS 1431, 2010 WL 1741105
CourtUnited States Bankruptcy Court, W.D. Texas
DecidedApril 29, 2010
Docket18-32173
StatusPublished
Cited by7 cases

This text of 429 B.R. 570 (In Re Introgen Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Introgen Therapeutics, Inc., 429 B.R. 570, 2010 Bankr. LEXIS 1431, 2010 WL 1741105 (Tex. 2010).

Opinion

MEMORANDUM OPINION CONFIRMING DEBTOR’S PLAN OF REORGANIZATION

CRAIG A. GARGOTTA, Bankruptcy Judge.

Introgen Therapeutics, Inc. and Intro-gen Technical Services, Inc. (together *574 “Debtors”) submitted their Amended Disclosure Statement on July 24, 2009, and their Modified Plan of Reorganization on October 7, 2009. Classes 1, 2, and 4 voted to accept the Plan, while Class 3 rejected the Plan and joined the United States Trustee’s motion to convert the case to Chapter 7. A hearing was held on October 8, 2009 to consider the Debtors’ Modified Plan of Reorganization. At trial, representatives for Debtors appeared, as did representatives for several of Debtors’ creditors — Wilson Sonsini Goodrich & Ro-sati, P.C. (“Wilson Sonsini”), David Nance, Wilson & Varner, Westat, Inc. (collectively referred to as “Creditors”), and the United States Trustee' — -to determine whether Debtors’ Plan could be approved. All creditors present at the hearing, except for the United States Trustee, are members of Class 3 — Allowed General Unsecured Claims. After the trial, several matters were taken under advisement and parties were given an opportunity to submit briefs in support of their position. Creditors’ main contentions are that the Plan does not have an impaired accepting class, that substantive consolidation is improper for the Debtors, and that the Plan violates the absolute priority rule.

The Court has reviewed the briefs of Debtors and the various creditors and has considered the arguments and evidence of counsel. Based on the foregoing, the Court finds that the Plan as modified is confirmable and satisfies all confirmation requirements under 11 U.S.C. § 1129 for the reasons stated below.

The Court has jurisdiction over this matter pursuant to 28 U.S.C. §§ 157 and 1334. This matter is a core proceeding pursuant to 28 U.S.C. § 157(b)(2)(L) and (O) on which this Court can enter a final judgment. This matter is referred to the Court under the District’s Standing Order of Reference. Venue is proper under 28 U.S.C. §§ 1408 and 1409. The following represents the Court’s findings of fact and conclusions of law made pursuant to Federal Rules of Bankruptcy Procedure 7052 and 9014.

Background op Debtor

Prior to filing for bankruptcy, Introgen Therapeutics, Inc. (“Introgen”) was a bio-pharmaceutical company focused on the discovery, development, and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen developed product candidates to treat a wide range of cancers using various techniques. Introgen’s development program included five clinical-stage product candidates in various phases of development. In June 2008, Introgen submitted a Biologies License Application to the U.S. Food and Drug Administration (“FDA”) requesting marketing approval for one of their product candidates. Also in June, a non-debtor European subsidiary of Introgen, Gendux Molecular Limited, submitted a Marketing Authorization Application to the European Medicines Evaluation Agency for the same indication. In addition to developing treatments, at the time of filing, Introgen controlled a broad intellectual property portfolio which included more than 400 patent applications and issued patents for a variety of molecular therapy technologies and adenovirus production, purification, and formulation.

In June 2008, Introgen, in an effort to create further revenue, spun off its manufacturing facilities and formed Introgen Technical Services, Inc. (“ITS”), a wholly-owned subsidiary of Introgen. According to Introgen’s 2008 Third Quarter 10-K, at the inception of ITS, Introgen anticipated that ITS would (1) assume responsibility for producing investigative materials for Introgen’s clinical trials; (2) produce and provide Introgen commercial supplies of products for which Introgen may receive *575 marketing approval from the appropriate regulatory agencies; and (3) pursue contract production, process development, and manufacturing services for third parties. (Debtor’s Ex. 7-D, 25.) ITS assumed responsibility for overseeing and managing the resources used in Introgen’s manufacturing activities, and employed and managed the personnel required to continue those processes. (Id.)

Circumstances Leading to Bankruptcy

According to the Debtor’s Amended Disclosure Statement, a 2009 regulatory setback before the FDA harmed the prospects for a speedy approval of Introgen’s cancer drug, Advexin, resulting in a liquidity crisis. As a result of this setback, Debtors were unable to move forward with plans of marketing and selling the drug. Continuing expenditures and significant operating losses precipitated the filing of the Debtors’ bankruptcy cases. The Debtors experienced a cash drain related mostly to, in the words of Debtors’ first Disclosure Statement, attorneys’ fees and an inefficient operating style. (Doc. # 292, p. 14.)

Post-Petition Activity of the Debtors

After considering the various options available to Debtors, the Debtors concluded that the best course of action for both creditors and holders of equity interests would be to engage in an orderly disposition of the Debtors’ assets and to wind down the remaining affairs through a liquidating trust. Throughout their bankruptcy eases, the Debtors continued to perform work in the ordinary course of business. The Debtors also produced biological materials for two key customers, Advanta-geme, Inc. and the H. Lee Moffitt Cancer Center.

Pursuant to Debtors’ decision to liquidate the assets, the significant events in Debtors’ Chapter 11 proceedings have been the disposition of their assets. On April 23, 2009, this Court approved the sale of certain contract manufacturing assets to Crucell Holland, B.V. (“Crucell”). Crucell purchased eight patent families from Introgen (the “Crucell Patents”) for $425,000. Additionally, Introgen retained a 35% share of all net license revenues, royalties, and proceeds received by Crucell and its affiliates, in connection with the licensing of the Crucell Patents to begin on May 15, 2009 and to last in perpetuity.

On April 27, 2009, this Court approved the sale of ITS’ contract manufacturing business to Vivante GMP Solutions, Inc. (“Vivante”), an affiliate of Western General Holding Company. On June 1, 2009, the Debtors and Vivante executed an asset purchase agreement under which Vivante agreed to pay $50,000 to Debtors and in exchange Debtors would receive, on a quarterly basis, an amount equal to three percent (3%) of all gross revenues and proceeds received by Vivante derived from or arising from the purchased assets.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Untitled Case
M.D. Louisiana, 2026
Untitled Case
M.D. Louisiana, 2026
Untitled Case
M.D. Louisiana, 2026
Untitled Case
M.D. Louisiana, 2026
In re ADPT DFW Holdings, LLC
574 B.R. 87 (N.D. Texas, 2017)
Yaquinto v. Ward (In re Ward)
558 B.R. 771 (N.D. Texas, 2016)
In re Carroll
520 B.R. 491 (M.D. Louisiana, 2014)
In re Mangia Pizza Investments, LP
480 B.R. 669 (W.D. Texas, 2012)
In re AHF Development, Ltd.
462 B.R. 186 (N.D. Texas, 2011)
In Re Cyberco Holdings, Inc.
431 B.R. 404 (W.D. Michigan, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
429 B.R. 570, 2010 Bankr. LEXIS 1431, 2010 WL 1741105, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-introgen-therapeutics-inc-txwb-2010.